Lipocine announces financial results for the second quarter ended june 30, 2023

Salt lake city , aug. 10, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders, today announced financial results for the second quarter and six months ended june 30, 2023, and provided a corporate update. clinical program highlights neuroactive steroids lipocine announced positive topline results from a pilot pharmacokinetics ("pk") bridge study of lpcn 1154 (oral brexanolone).
LPCN Ratings Summary
LPCN Quant Ranking